Rapid Novor

Rapid Novor provides commercial next-generation protein sequencing services with a focus on direct de novo antibody sequencing using proprietary mass spectrometry and bioinformatics platforms. Their technology enables the discovery and characterization of antibodies without requiring access to the producing cell line. The company has sequenced over ten thousand antibodies, supporting thousands of research projects worldwide. Their first proprietary clinical product, the EasyM™ blood test for multiple myeloma minimal residual disease monitoring, has achieved CLIA certification in the US and entered prospective clinical trials in Canada.